Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 9:00 AM CET
Settings

Settings

Goto Application

1. WO2022008902 - METHOD FOR TREATING A GD2-POSITIVE CANCER

Publication Number WO/2022/008902
Publication Date 13.01.2022
International Application No. PCT/GB2021/051721
International Filing Date 06.07.2021
IPC
C07K 16/30 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
A61K 39/395 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 43/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
A61K 31/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
A61K 33/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
Applicants
  • EUSA PHARMA (UK) LIMITED [GB]/[GB]
Inventors
  • LODE, Holger Nikolaus
  • LADENSTEIN, Ruth
Agents
  • LINEHAN, Sheena Alice
Priority Data
20305766.606.07.2020EP
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) METHOD FOR TREATING A GD2-POSITIVE CANCER
(FR) PROCÉDÉ DE TRAITEMENT D'UN CANCER POSITIF POUR GD2
Abstract
(EN) A method of treating a newly diagnosed neuroblastoma in a patient by administering chimeric anti-GD2 antibody dinutuximab beta to the patient in combination with induction chemotherapy. The chimeric anti-GD2 antibody dinutuximab beta is administered at a cumulative dose of up to 500 mg/m2, and/or in a dose of up to 100 mg/m2 per cycle during one or more cycles of induction chemotherapy, and/or at a treatment density of up to 5 mg/m2/day.
(FR) Procédé de traitement d'un neuroblastome nouvellement diagnostiqué chez un patient par l'administration d'anticorps anti-GD2 chimérique dinutuximab bêta au patient en combinaison avec une chimiothérapie par induction. L'anticorps anti-GD2 chimérique dinutuximab bêta est administré selon une dose cumulée allant jusqu'à 500 mg/m2, et/ou selon une dose allant jusqu'à 100 mg/mm2 par cycle pendant un ou plusieurs cycles de chimiothérapie par induction, et/ou selon une densité de traitement allant jusqu'à 5 mg/m2/jour.
Latest bibliographic data on file with the International Bureau